Insights

Avita Medical share price tumbles 7% on declining Q1 revenue

The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.
The post Avita Medical share price tumbles 7% on declining Q1 revenue appeared first on The Motley Fool Australia. –

The Avita Medical Inc (ASX: AVH) share price is down 7.2% to $1.62 in early trade.

Avita focuses on regenerative medicines. Its spray-on Recell medicine is used to treat burn patients.

Below we look at the ASX healthcare share’s first-quarter results for the three months ending 31 March (Q1 2022).

What was reported for the quarter?

The Avita Medical share price is sliding after the company a 14% decrease in revenue compared to Q1 2021. Revenue for the quarter came in at $7.5 million.

The company reported the decline was largely due to its recognition of $4.1 million in Biomedical Advanced Research and Development Authority (BARDA) related revenue in 2021.

Avita’s Q1 2022 commercial revenue increased 61% year-on-year to $2.8 million. It attributed the lift to “broader utilisation among our customer base as well as deeper penetration within individual customer accounts”.

Gross profits of $5.7 million were down 13% from the $6.6 million reported in the prior corresponding period. Gross profit margin of 76% was identical to Q1 2021.

Operating expenses increased $2.8 million to $16.0 million, 21% higher than the corresponding quarter.

On the bottom line, and likely pressuring the Avita Medical share price today, the company reported a net loss of $9.5 million. That’s 58% more than the $6.0 million net loss reported for the first three months of 2021.

What’s next?

The company intends to use its cash reserves until US sales of its products ramp up to levels where those revenues can fund its ongoing operations. As at 31 March, Avita reported it has enough cash reserves to fund operations for the next 12 months.

Avita added, “We have no committed plans to issue further shares on the market.”

As for dividends?

“There were no dividends paid and we have no plans to commence the payment of dividends.”

Avita Medical share price snapshot

With this morning’s intraday losses factored in, the Avita Medical share price is down a painful 53% in 2022. That compares to a year-to-date loss of 9% posted by the All Ordinaries Index (ASX: XAO).

The post Avita Medical share price tumbles 7% on declining Q1 revenue appeared first on The Motley Fool Australia.

Should you invest $1,000 in Avita Medical right now?

Before you consider Avita Medical, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Avita Medical wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

More reading

Why Tesla stock is falling again today
Which is the better beaten-up buy, Bubs or A2 Milk shares?
Infomedia share price halted amid takeover approach
Own ASX 200 retail shares? Here’s how the majors are tackling climate change
Is the BHP share price too exposed to the downside risks of China?

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!